Sulbactam-durlobactam: a ß-lactam/ß-lactamase inhibitor combination targeting Acinetobacter baumannii.
Future Microbiol
; 19(7): 563-576, 2024.
Article
in En
| MEDLINE
| ID: mdl-38426849
ABSTRACT
Sulbactam-durlobactam is a pathogen-targeted ß-lactam/ß-lactamase inhibitor combination that has been approved by the US FDA for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii-calcoaceticus complex (ABC) in patients 18 years of age and older. Sulbactam is a penicillin derivative with antibacterial activity against Acinetobacter but is prone to hydrolysis by ß-lactamases encoded by contemporary isolates. Durlobactam is a diazabicyclooctane ß-lactamase inhibitor with activity against Ambler classes A, C and D serine ß-lactamases that restores sulbactam activity both in vitro and in vivo against multidrug-resistant ABC. Sulbactam-durlobactam is a promising alternative therapy for the treatment of serious Acinetobacter infections, which can have high rates of mortality.
Sulbactamdurlobactam a drug for treating lung infectionsAcinetobacter is a type of bacteria. One type, called CRAB, causes serious infections and can be fatal. CRAB is very hard to treat because most drugs no longer work. Sulbactamdurlobactam (SUL-DUR) is a drug that can kill CRAB. The US FDA approved SUL-DUR in May of 2023 for treating lung infections (pneumonia) caused by CRAB. This article explains how SUL-DUR works. Use of SUL-DUR and other drugs to treat these types of infections are discussed. In conclusion, SUL-DUR is a promising therapy for serious infections caused by CRAB.
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Acinetobacter Infections
/
Sulbactam
/
Acinetobacter baumannii
/
Azabicyclo Compounds
/
Beta-Lactamase Inhibitors
/
Anti-Bacterial Agents
Limits:
Animals
/
Humans
Language:
En
Journal:
Future Microbiol
/
Future microbiol., (Print)
/
Future microbiology (Print)
Journal subject:
MICROBIOLOGIA
Year:
2024
Type:
Article
Affiliation country:
United States